Purple Biotech (PPBT) Gains from Investment Securities (2014 - 2019)

Purple Biotech (PPBT) has reported Gains from Investment Securities for 4 consecutive years, with -$522000.0 the latest figure, recorded in Q4 2019.

• On a quarterly basis, Gains from Investment Securities rose 83.0% year-over-year to -$522000.0 in Q4 2019; TTM through Dec 2019 was -$3.5 million, a 14.57% decrease from a year earlier, with the FY2019 full-year figure at -$1.5 million, up 34.47% from the prior year.
• Gains from Investment Securities was -$522000.0 for Q4 2019 at Purple Biotech, up from -$3.1 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $63000.0 in Q3 2015 and troughed at -$3.1 million in Q4 2018.
• A 3-year average of -$878500.0 and a median of -$253500.0 in 2015 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 120.0% in 2015, down 3.28% in 2015.
• Over 3 years, Gains from Investment Securities stood at $15000.0 in 2015, then sank by 20566.67% to -$3.1 million in 2018, then surged by 83.0% to -$522000.0 in 2019.
• The last three Gains from Investment Securities figures came in at -$522000.0 (Q4 2019), -$3.1 million (Q4 2018), and $15000.0 (Q4 2015), per Business Quant data.